Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025

EQS-News: Pentixapharm Holding AG / Key word(s): Study results/Research Update Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025 (news with additional features) 06.10.2025 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement.

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with
New Clinical Findings at EANM 2025
 

• Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism
• First-in-human findings with [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer show early therapeutic activity, further validating CXCR4 as a clinically relevant target
   

Berlin, Germany, October 6, 2025 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today announced the presentation of extensive clinical data from independent investigator-initiated studies assessing Pentixapharm’s CXCR4-targeting diagnostic lead candidate, [⁶⁸Ga]Ga-PentixaFor, at the ongoing Annual Congress of the European Association of Nuclear Medicine (EANM 2025) in Barcelona, Spain.

At EANM 2025, four oral presentations and seven e-posters feature new data on [⁶⁸Ga]Ga-PentixaFor PET/CT imaging in Primary Aldosteronism (PA) – a condition frequently underdiagnosed despite being one of the leading causes of secondary hypertension. These presentations include comparative clinical trial results, evaluating [⁶⁸Ga]Ga-PentixaFor against adrenal venous sampling (AVS), the current invasive gold standard for subtyping PA. The data demonstrate the high potential of [⁶⁸Ga]Ga-PentixaFor to significantly improve subtyping of patients, thereby enabling better therapy decisions, and more precise patient management in PA.

Complementing these results in cardiovascular and endocrine disease, the scientific program at EANM 2025 also showcases the expanding role of Pentixapharm’s CXCR4-targeted platform in oncology. Among the highlights are first-in-human data on Pentixapharm’s therapeutic candidate [¹⁷⁷Lu]Lu-PentixaTher, in patients with bladder cancer. The early findings demonstrate initial signs of therapeutic activity, adding to the growing body of evidence supporting [¹⁷⁷Lu]Lu-PentixaTher as a precision treatment candidate for CXCR4-positive malignancies.